| Accession | SAMC1674728 |
|---|---|
| Accession in Other Database | GSA-Human: HRS169130 |
| Sample name | LJP1 |
| Title | NUP214-ABL1 |
| Sample type | Human sample |
| Organism | Homo sapiens |
| Description | acute myeloid leukemia. Bone marrow (BM) aspiration revealed 78% blast cells. The blast cells were positive for CD7, CD117, CD34, CD33, CD13, HLA-DR, CD38 (dim), CD123, CD56 (partial) and c-MPO by flow cytometry. |
| Attributes | *This sample record contains additional controlled-access information that is avaiable from GSA-Human by requesting study HRA000867 in the GSA-Human system. |
| Release date | 2021-05-27 |
| BioProject Accession | PRJCA005089 |
| Submitter | Huanping Wang (jiej0503@zju.edu.cn) |
| Organization | the First Affiliated Hospital, College of Medicine, Zhejiang University |
| Submission date | 2023-06-18 |
| Resource name | Description |
|---|---|
| GSA-Human (1) | - |
| HRA000867 (Controlled Access) | The NUP214-ABL1 is a constitutively active tyrosine kinase that is found in 6% of T-cell acute lymphoblastic leukemia (T-ALL) patients; however the NUP214-ABL1 fusion in acute myeloid leukemia (AML) has not yet been reported. Up to now, the sensitivity of NUP214-ABL1-positive patients to tyrosine kinase inhibitor (TKI) is still controversial. Here we report the first case of an AML patient with NUP214-ABL1 fusion gene. The patient was successfully treated with conventional AML chemotherapy regimens. Identification of additional AML patients with NUP214-ABL1 fusion gene will provide treatment experience and prognostic evaluation. |